BNP (Brain Natriuretic Peptide)

Overview

Brain natriuretic peptide (BNP), despite its name, is predominantly a cardiac hormone — a 32-amino-acid peptide synthesized and secreted primarily by ventricular cardiomyocytes in response to myocardial wall stress caused by volume overload and pressure overload. BNP was originally isolated from porcine brain tissue in 1988 by Toshio Sudoh and colleagues, which accounts for its "brain" designation, but subsequent research established the ventricles as its principal physiological source.

BNP is a member of the natriuretic peptide family, which includes atrial natriuretic peptide (ANP, produced by atrial cardiomyocytes), BNP, and C-type natriuretic peptide (CNP, produced by endothelium and the central nervous system). All three endogenous peptides share the common functions of promoting natriuresis (sodium excretion), diuresis, and vasodilation — collectively serving as a counter-regulatory system opposing the sodium-retaining and vasoconstrictive effects of the renin-angiotensin-aldosterone system (RAAS) and endothelin signaling.

BNP's primary clinical significance lies in its role as a cardiac biomarker. Measurement of BNP or its more stable cleavage byproduct NT-proBNP (N-terminal pro-BNP) has become indispensable in the diagnosis, risk stratification, and management of heart failure. Elevated BNP levels correlate with the severity of ventricular dysfunction and provide prognostic information across the spectrum of cardiovascular disease.

The synthetic recombinant form of BNP, nesiritide (Natrecor), was approved by the FDA in 2001 for the treatment of acute decompensated heart failure, though its clinical role has been circumscribed by safety concerns and the availability of alternative therapies.

Structure and Sequence

Human BNP-32 sequence: Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His

• Molecular weight: approximately 3,464 g/mol
• Gene: NPPB (chromosome 1p36.22), located in a cluster with NPPA (encoding ANP)
• Precursor: PreproBNP (134 amino acids) is processed to proBNP (108 amino acids), which is cleaved by the proprotein convertases corin and furin to yield:
  • BNP-32 (C-terminal fragment, residues 77-108) — the biologically active hormone
  • NT-proBNP (N-terminal fragment, residues 1-76) — the biologically inactive but diagnostically valuable byproduct

Key structural features:

• Disulfide bridge: Cys10-Cys26 creates a 17-residue ring structure essential for receptor binding and biological activity
• Ring structure conservation: The disulfide-constrained ring is the common structural motif across all natriuretic peptides; the ring sequence determines receptor selectivity
• N- and C-terminal tails: Flanking sequences outside the ring contribute to receptor affinity and metabolic stability
• Glycosylation of proBNP: The proBNP precursor undergoes O-glycosylation, which can impair cleavage to BNP-32 and NT-proBNP, generating circulating glycosylated proBNP forms that confound some immunoassays

BNP vs. NT-proBNP as biomarkers:

• BNP-32: half-life approximately 20 minutes; cleared by natriuretic peptide receptor C (NPR-C) and neprilysin (NEP)
• NT-proBNP: half-life approximately 120 minutes; cleared primarily by renal excretion; more stable and often preferred for clinical assays

Mechanism of Action

Natriuretic Peptide Receptor Signaling

BNP signals primarily through natriuretic peptide receptor A (NPR-A, also called guanylyl cyclase A), a single-pass transmembrane receptor with intrinsic guanylyl cyclase activity, part of the broader signal transduction network:

Signal transduction:

• BNP binding activates the intracellular guanylyl cyclase domain, increasing cyclic GMP (cGMP) production
• cGMP activates protein kinase G (PKG), phosphodiesterases (PDE2, PDE3), and cGMP-gated ion channels
• Additional clearance occurs through NPR-C (a clearance receptor without guanylyl cyclase activity) and enzymatic degradation by neprilysin

Renal Effects:

• Afferent arteriole vasodilation and efferent arteriole vasoconstriction increase glomerular filtration rate (GFR) and filtered sodium load
• Direct inhibition of sodium reabsorption in the inner medullary collecting duct
• Suppression of renin secretion from juxtaglomerular cells
• Inhibition of aldosterone synthesis and secretion from the adrenal zona glomerulosa
• Net effect: natriuresis, diuresis, and reduction in intravascular volume

Cardiovascular Effects:

• Systemic venous and arterial vasodilation, reducing both preload and afterload
• cGMP-mediated smooth muscle relaxation in resistance and capacitance vessels
• Inhibition of cardiac fibroblast proliferation and collagen synthesis (anti-fibrotic)
• Reduction in cardiac hypertrophy through inhibition of hypertrophic signaling pathways (calcineurin/NFAT, MAPK)
• Anti-inflammatory effects on vascular endothelium

Neurohumoral Modulation:

• Suppression of sympathetic nervous system activity
• Inhibition of RAAS at multiple levels (renin, angiotensin II, aldosterone)
• Reduction of endothelin-1 production
• Inhibition of vasopressin (ADH) secretion

Stimulus for BNP Release

BNP secretion from ventricular cardiomyocytes is stimulated by:

• Ventricular wall stretch (the primary stimulus — volume and pressure overload)
• Myocardial ischemia and infarction
• Neurohormonal activation (angiotensin II, endothelin-1, catecholamines)
• Inflammatory cytokines
• Hypoxia

Unlike ANP, which is stored in preformed granules in atrial cardiomyocytes, BNP is synthesized on demand from gene transcription in response to ventricular stress. This transcriptional regulation makes BNP a more specific marker of ventricular pathology.

Research Summary

Pharmacokinetics

Endogenous BNP:

• Plasma half-life: Approximately 20 minutes for BNP-32; approximately 120 minutes for NT-proBNP
• Clearance mechanisms: NPR-C receptor-mediated internalization and lysosomal degradation; neprilysin (neutral endopeptidase) enzymatic cleavage; minor renal clearance
• Normal plasma levels: BNP: <100 pg/mL (general reference); NT-proBNP: age-dependent cutoffs (<300 pg/mL to exclude heart failure in acute settings)
• Factors elevating BNP beyond heart failure: Advanced age, renal insufficiency, atrial fibrillation, pulmonary hypertension, pulmonary embolism, sepsis, critical illness
• Factors inappropriately lowering BNP: Obesity (BNP levels are paradoxically lower in obese individuals with heart failure, likely due to increased NPR-C-mediated clearance in adipose tissue)
• Assay considerations: Point-of-care BNP assays detect BNP-32 and some cross-react with proBNP; NT-proBNP assays have longer sample stability but are affected by renal function

Nesiritide (synthetic BNP):

• Half-life: Approximately 18 minutes
• Administration: Intravenous bolus followed by continuous infusion (2 mcg/kg bolus, then 0.01 mcg/kg/min)
• Onset: Hemodynamic effects within 15 minutes of infusion
• Duration: Effects dissipate within 30-60 minutes of infusion discontinuation
• Clearance: Same as endogenous BNP — NPR-C binding, neprilysin degradation, and renal filtration

Common Discussion Topics

BNP in heart failure diagnosis: The introduction of BNP and NT-proBNP testing transformed the emergency department evaluation of dyspnea. Natriuretic peptide levels effectively distinguish cardiac from pulmonary causes of acute shortness of breath, guide treatment intensity, and provide discharge prognosis. The "Breathing Not Properly" study established BNP testing as a standard of care, and current heart failure guidelines incorporate natriuretic peptide measurement into the diagnostic algorithm.

The obesity paradox: BNP levels are disproportionately lower in obese patients with heart failure compared to non-obese patients with equivalent cardiac dysfunction. This "BNP ceiling" is attributed to increased clearance by NPR-C receptors in adipose tissue and reduced BNP synthesis per unit of myocardial mass. Clinicians must use lower diagnostic thresholds in obese patients to avoid underdiagnosis.

Sacubitril/valsartan and neprilysin inhibition: The landmark PARADIGM-HF trial demonstrated that inhibiting neprilysin (the enzyme that degrades natriuretic peptides, including BNP) combined with angiotensin receptor blockade produced superior outcomes to ACE inhibition alone in heart failure with reduced ejection fraction. This validated the therapeutic strategy of augmenting endogenous natriuretic peptide signaling. Neprilysin inhibition also raises bradykinin levels, contributing additional vasodilatory effects.

Nesiritide's limited clinical role: Despite initial enthusiasm and FDA approval, nesiritide (recombinant BNP) fell from favor following concerns about renal toxicity and mortality. The ASCEND-HF trial demonstrated modest symptomatic benefit without mortality improvement or significant renal harm, but the marginal benefit relative to cost limited its adoption. Nesiritide exemplifies the principle that administering supraphysiological doses of an endogenous peptide does not necessarily replicate the benefits of enhancing endogenous production.

NT-proBNP vs. BNP for clinical use: Both biomarkers are widely used, with different clinical characteristics. NT-proBNP has a longer half-life (more stable for laboratory processing), is not affected by neprilysin inhibition (important for monitoring patients on sacubitril/valsartan), but is more strongly influenced by renal function and age. BNP assays are available as point-of-care tests, enabling rapid bedside decision-making.

Dosing Protocols

As an endogenous cardiac hormone, BNP is primarily used clinically as a diagnostic and prognostic biomarker for heart failure (measured as BNP or NT-proBNP in blood tests). The recombinant form of BNP, nesiritide (Natrecor), is the FDA-approved therapeutic preparation — see the nesiritide article for clinical dosing protocols.

Related Compounds

• Bradykinin — vasoactive peptide also degraded by neprilysin; co-elevated during neprilysin inhibition
• Endothelin-1 — vasoconstrictive and fibrotic peptide whose effects are functionally opposed by BNP signaling
• CGRP — vasodilatory neuropeptide with complementary cardiovascular effects